Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.
IPO Year: 2007
Exchange: NASDAQ
Website: accuray.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/13/2024 | $9.00 | Buy | ROTH MKM |
6/23/2022 | $7.50 | Buy | B. Riley Securities |
12/22/2021 | $7.50 | Buy | Loop Capital |
4 - ACCURAY INC (0001138723) (Issuer)
Accuray is the first industry partner to open a facility at the Genolier Innovation Hub, created to provide opportunities for clinician-industry collaborations that can help accelerate improvements in patient careNew Accuray CyberComm™ tool was used to significantly reduce the CyberKnife® S7™ System's commissioning time and enable product training in Genolier to begin more quicklyMADISON, Wis., Sept. 30, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the initiation of CyberKnife® S7™ System medical professional training at its education center located within the newly opened Genolier Innovation Hub, a fully-owned subsidiary of AEVIS VICTORIA SA, in Switzerland. As th
The Technology Will Play an Important Role in the Hospital's Plan to Expand Patient Access to High Precision Radiation Therapy Treatments MADISON, Wis., Sept. 10, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Gifu Prefectural General Medical Center is setting a new standard in cancer care in Japan as the first hospital in the country to treat patients with surface-guided radiation therapy (SGRT) using the company's Radixact® Radiation Delivery System and VitalHold™* package. SGRT is designed to help medical care teams to effectively position the patient and confidently monitor the accuracy of that positioning throughout treatment. The ability to confidently mon
MADISON, Wis., Sept. 3, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that President and Chief Executive Officer Suzanne Winter will be taking a temporary medical leave of absence to receive care for a treatable form of cancer, effective immediately. Accuray Senior Vice President and Chief Commercial Officer Sandeep Chalke will serve as the interim CEO during Ms. Winter's absence. To ensure that Mr. Chalke and the organization have the necessary support, the company has formed an Executive Committee of the Board of Directors, consisting of Joseph Whitters, Chairman of the Accuray Board, and Anne Le Grand, Chair of the Science and Technology Committee, that will advi
Developed for India and other countries where patient access to care with radiotherapy is challenged and where versatility and ease of use are a high priorityDrives the next phase of company's strategic plan to expand its portfolio of helical radiation therapy delivery systemsMADISON, Wis., Aug. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the company has received CE Mark for Accuray Helix™, a CT-guided helical radiotherapy system designed to provide high-performance and high-throughput. The new system is intended for emerging markets where access to advanced cancer care, including radiotherapy treatments, is typically obtainable only within urban areas and whe
14% Revenue and 8% Orders Growth in Q4; Company issues FY25 Guidance MADISON, Wis., Aug. 14, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the fourth quarter and fiscal 2024, ended June 30, 2024. Fourth Quarter Fiscal 2024 Summary Net revenue of $134.3 million, an increase of 13.5 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $136.7 million, which represents a 15.6 percent increase versus the same period in the prior fiscal year.GAAP net income of $3.4 million, as compared to G
New Technology Provides Advanced Patient Positioning Capabilities With the Radixact System, Making it Easier to Deliver Fast and Effective Radiotherapy Treatments MADISON, Wis. and DAYTONA BEACH, Fla., Aug. 13, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) and Halifax Health, in Volusia County, Florida, announced today that the Charles L. and Miki N. Grant Cancer Center for Hope medical team is the first in the U.S. to treat cancer patients using the Accuray Radixact® System with VitalHold™* technology. The new VitalHold feature will provide a resource for effectively positioning the patient and monitoring the accuracy of that positioning throughout their treatment, enhancing preci
MADISON, Wis., July 31, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the fourth quarter of fiscal year 2024, ended June 30, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on August 14, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (internationa
The Radixact System will be supplied with ClearRT®, Synchrony®, and the VOLO™ Ultra Optimizer to enhance radiation treatment delivery precision and speedHeidelberg University Hospital is recognized worldwide for excellence in patient care and practice changing researchMADISON, Wis., June 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that long-term customer Heidelberg University Hospital in Heidelberg, Germany, has selected the company's Radixact® System, equipped with its proprietary ClearRT®, Synchrony® and VOLO™ Ultra Optimizer solutions, to help transform their approach to cancer care. The full-featured system is designed to help provide the certainty necessa
MADISON, Wis., June 20, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today an agreement with TrueNorth Medical Physics LLC to provide radiation oncology departments with third-party support designed to enhance their department's capabilities. Under the terms of the agreement, TrueNorth Medical Physics will offer services that are complementary and supplementary to those supplied by Accuray, acting as an extension of the hospital team – on-site, remote or hybrid – to help ensure they have the staffing needed to achieve patient treatment goals. As the field
MADISON, Wis., June 12, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that the registration dossier for the Accuray Precision® Treatment Planning System (TPS) has been approved by the Chinese National Medical Products Administration (NMPA). The Accuray Precision TPS is now available for use with the CNNC-Accuray joint venture Tomo® C radiation therapy system and in combination, will provide medical care teams with a new option for delivering extremely precise and accurate radiotherapy treatments, ultimately expanding access to care for more cancer patients in China.
DEFA14A - ACCURAY INC (0001138723) (Filer)
DEF 14A - ACCURAY INC (0001138723) (Filer)
10-K - ACCURAY INC (0001138723) (Filer)
NT 10-K - ACCURAY INC (0001138723) (Filer)
8-K - ACCURAY INC (0001138723) (Filer)
8-K - ACCURAY INC (0001138723) (Filer)
8-K - ACCURAY INC (0001138723) (Filer)
SD - ACCURAY INC (0001138723) (Filer)
8-K - ACCURAY INC (0001138723) (Filer)
10-Q - ACCURAY INC (0001138723) (Filer)
14% Revenue and 8% Orders Growth in Q4; Company issues FY25 Guidance MADISON, Wis., Aug. 14, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the fourth quarter and fiscal 2024, ended June 30, 2024. Fourth Quarter Fiscal 2024 Summary Net revenue of $134.3 million, an increase of 13.5 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $136.7 million, which represents a 15.6 percent increase versus the same period in the prior fiscal year.GAAP net income of $3.4 million, as compared to G
MADISON, Wis., July 31, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the fourth quarter of fiscal year 2024, ended June 30, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on August 14, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (internationa
MADISON, Wis., May 1, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the third quarter and nine-months ended March 31, 2024. Third Quarter Fiscal 2024 Summary Net revenue of $101.1 million decreased 14 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $102.4 million, which represented a 13 percent decrease from the same period in the prior fiscal year.GAAP net loss was $6.3 million, as compared to GAAP net income of $0.6 million in the same period in the prior fiscal year. Adjusted
MADISON, Wis., April 17, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 1, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is (877) 344-7529 (USA) or (412) 317-0088 (international),
19% Order Growth YOY; 8% Service Revenue Expansion; Confirms FY24 Guidance MADISON, Wis., Jan. 31, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter and six-months ended December 31, 2023. Second Quarter Fiscal 2024 Summary Net revenue of $107.2 million increased 3 percent sequentially and decreased 7 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $106.0 million, which represented an 8 percent decrease from the same period in the prior fiscal year.GAAP net loss w
MADISON, Wis., Jan. 16, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on January 31, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is (877) 344-7529 (USA) or (412) 317-0088 (interna
8% Q4 revenue growth; Record shipments for FY23; Company issues guidance for FY24 MADISON, Wis., Aug. 9, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the fourth quarter and fiscal 2023, ended June 30, 2023. Fourth Quarter Fiscal 2023 Summary Net revenue of $118.3 million, an increase of 7.5 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $120.1 million, which represents a 9.1 percent increase versus the same period in the prior fiscal year.GAAP net loss of $2.6 million, as co
SUNNYVALE, Calif., July 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the fourth quarter and fiscal year 2023, ended June 30, 2023, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on August 9, 2023. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is (877) 344-7529 (USA) or (412) 317-0088 (internat
Company delivers record quarterly revenue and unit volume in Q3; Reiterates fiscal year guidance SUNNYVALE, Calif., April 26, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the third quarter of fiscal 2023 ended March 31, 2023. Third Quarter Fiscal 2023 Summary Net revenue of $118.1 million increased 22.8 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $122.1 million, which represents a 27.0 percent increase versus the same period in the prior fiscal year.GAAP net income of $0.6
SUNNYVALE, Calif., April 13, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2023, ended March 31, 2023, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on April 26, 2023. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is (877) 344-7529 (USA) or (412) 317-0088 (internat
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
SC 13G/A - ACCURAY INC (0001138723) (Subject)
ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00
B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50
Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50
Under the terms of the agreement, TrueNorth Medical Physics will offer services that are complementary and supplementary to those supplied by Accuray, acting as an extension of the hospital team – on-site, remote or hybrid
Accuray Incorporated (NASDAQ:ARAY) announced today that the registration dossier for the Accuray Precision® Treatment Planning System (TPS) has been approved by the Chinese National Medical Products Administration (NMPA). The Accuray Precision TPS is now available for use with the CNNC-Accuray joint venture Tomo® C radiation therapy system and in combination, will provide medical care teams with a new option for delivering extremely precise and accurate radiotherapy treatments, ultimately expanding access to care for more cancer patients in China.
Gainers MyMD Pharmaceuticals (NASDAQ:MYMD) stock rose 46.0% to $2.89 during Thursday's after-market session. The market value of their outstanding shares is at $6.6 million. Adaptimmune Therapeutics (NASDAQ:ADAP) stock moved upwards by 31.68% to $1.33. The market value of their outstanding shares is at $339.8 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) shares moved upwards by 12.83% to $0.33. BiomX (AMEX:PHGE) stock rose 6.24% to $0.44. The market value of their outstanding shares is at $31.0 million. Virios Therapeutics (NASDAQ:VIRI) stock increased by 6.12% to $0.22. The market value of their outstanding shares is at $6.1 million. Accuray (NASDAQ:ARAY) stock increas
Gainers Emergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out yesterday. Nuwellis (NASDAQ:NUWE) stock moved upwards by 40.1% to $0.19. The market value of their outstanding shares is at $1.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) shares increased by 40.05% to $1.76. The company's market cap stands at $44.2 million. Syra Health (NASDAQ:SYRA) shares rose 36.26% to $1.42. The company's market cap stands at $9.3 million. Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.35% to $0.3. The company's market cap stands at $85.5 million. Titan Pha
Gainers Allarity Therapeutics (NASDAQ:ALLR) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. Emergent BioSolutions (NYSE:EBS) shares moved upwards by 52.84% to $2.95. The market value of their outstanding shares is at $154.5 million. As per the press release, Q1 earnings came out yesterday. Aptevo Therapeutics (NASDAQ:APVO) stock rose 35.41% to $1.3. The company's market cap stands at $4.6 million. Context Therapeutics (NASDAQ:CNTX) stock rose 34.55% to $1.83. The company's market cap stands at $29.2 million. Skye Bioscience (NASDAQ:SKYE) stock increased by 25.09% to $16.0. The company's market
Accuray (NASDAQ:ARAY) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.01) by 500 percent. This is a 700 percent decrease over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $101.132 million which missed the analyst consensus estimate of $113.649 million by 11.01 percent. This is a 14.34 percent decrease over sales of $118.060 million the same period last year.
Gainers Pulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out today. Butterfly Network (NYSE:BFLY) shares moved upwards by 18.15% to $0.93. The company's market cap stands at $193.5 million. As per the press release, Q1 earnings came out today. Compass Therapeutics (NASDAQ:CMPX) stock rose 11.46% to $1.75. The market value of their outstanding shares is at $240.7 million. Sharps Technology (NASDAQ:STSS) shares increased by 9.2% to $0.27. The market value of their outstanding shares is at $4.2 million. Blueprint Medicines (NASDAQ:BPMC) shares moved up
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
4 - ACCURAY INC (0001138723) (Issuer)
SUNNYVALE, Calif., Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Robert C. Kill to the company's Board of Directors, effective as of January 30, 2023. Mr. Kill is a skilled healthcare executive with more than 30 years' experience transforming various healthcare-related companies. In his most recent executive position as CEO of Parata Systems, Mr. Kill grew company revenue over 5X during his tenure before it sold last year for more than $1.5 billion. Before Parata, Mr. Kill was affiliated with two private equity funds, Frazie
LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the Company's U.S. subsidiary. During his extensive career, Mr. Mobeck has demonstrated significant leadership expertise in driving transformational business growth while establishing a track record of creating lasting shareholder value. Marc Oczachowski, Chairman and Chief Executive Officer of EDAP TMS, stated, "I am very pleased to welcome Ken onboard our U.S. subsidiary. Ken is a great addition to Ryan Rh
SUNNYVALE, Calif., June 15, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Franco N. Palomba has joined the company as vice president, chief accounting officer & controller. Mr. Palomba will be responsible for the controllership function, including the global accounting organization and associated budgetary and administrative operations, as well as financial and regulatory compliance. He will report to Accuray senior vice president & chief financial officer Ali Pervaiz. Mr. Palomba is a skilled executive with more than 30 years of accounting and f
SUNNYVALE, Calif., May 17, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Sandeep Chalke has joined the company as senior vice president, chief commercial officer effective May 16, 2022. Mr. Chalke will have responsibility for the global commercial, product development, R&D and engineering functions for the company reporting to Accuray president and forthcoming CEO, Suzanne Winter. Mr. Chalke brings more than 25 years of medical device expertise in commercialization, business development and operations, spanning multiple healthcare industry segmen
SUNNYVALE, Calif., Aug. 23, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Mika Nishimura to the company's Board of Directors, effective as of August 17, 2021. With Ms. Nishimura's appointment, the Accuray Board will consist of nine members. Ms. Nishimura also currently serves as an Independent Director on the Boards of SI-BONE, Inc., and MobileODT, and as a Board advisor to Tristel, plc. A commercial business executive with more than 25 years of global medical device industry experience, Ms. Nishimura has deep product commercialization experience across a broad range of innovative medical technologies.
SUNNYVALE, Calif., April 26, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Jean-Philippe Pignol, M.D., Ph.D. as its chief medical & technology officer, effective as of April 15, 2021. In this new role, Dr. Pignol will lead the company's scientific and clinical research activities, develop strategic collaborations with global key opinion leaders, evaluate new technologies and serve as the executive representative with important industry partners including medical societies, regulatory and legislative agencies that influence healthcare policy and reimbursement.
SUNNYVALE, Calif., Feb. 19, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Byron C. Scott, M.D., MBA to the company's Board of Directors, effective as of February 12, 2021. Dr. Scott brings significant experience as a physician executive with invaluable global expertise in healthcare analytics and technology. Dr. Scott is currently on the faculties at the University of Massachusetts, Amherst, Isenberg School of Management and Jefferson University, College of Population Health where he teaches healthcare quality, patient safety, and performance improvement. Previously, Dr. Scott served as Deputy Chief Health Officer at IBM Watson Health, where he s